The impact of the COVID-19 pandemic on patients with juvenile idiopathic inflammatory myopathies.
Juvenile idiopathic inflammatory myopathies
Pediatric rheumatology
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
12 Sep 2023
12 Sep 2023
Historique:
received:
16
06
2023
accepted:
06
08
2023
medline:
14
9
2023
pubmed:
13
9
2023
entrez:
12
9
2023
Statut:
epublish
Résumé
Throughout the COVID-19 pandemic, there have been concerns regarding the risks of infection in patients with autoimmune disease. In this study, we investigated the impact of the pandemic on patients with juvenile idiopathic inflammatory myopathies (JIIM). Data were collected using a patient/caregiver survey via Research Electronic Data Capture (REDCap) database. Eligibility included JIIM diagnosis and current age less than 21 years old. Surveys were distributed via the CureJM organization, social media, Childhood Arthritis and Rheumatology Research Alliance (CARRA) network and Dr. Peter Dent Pediatric Rheumatology Bulletin Board. Eighty-four respondents accessed the survey, 70 (83%) consented to participate, and 54 out of 70 completed the full survey (77%). Twenty-seven out of 57 patients (47%) tested positive for COVID-19, with 7 (12%) testing positive more than once. Despite broad usage of immunosuppressive medications, 24 out of 27 (89%) reported mild symptoms with none requiring hospitalization. Four patients reported a flare of JIIM symptoms after COVID-19; three of whom held immunomodulatory medications during their infection. Thirty-seven out of 54 respondents (69%) reported vaccination against COVID-19, with 9 out of 37 (24%) reporting minor vaccine side effects and one reporting JIIM flare post vaccination. Twenty-one out of 54 (39%) respondents reported psychosocial concerns related to the COVID-19 pandemic. Patients with JIIM, including those on multiple immunosuppressive medications, had mild symptoms related to COVID-19. Most patients tolerated COVID-19 vaccination well. Few patients had disease flare post-COVID-19 or vaccination. Mental health concerns were demonstrated in JIIM patients during the COVID-19 pandemic.
Sections du résumé
BACKGROUND
BACKGROUND
Throughout the COVID-19 pandemic, there have been concerns regarding the risks of infection in patients with autoimmune disease. In this study, we investigated the impact of the pandemic on patients with juvenile idiopathic inflammatory myopathies (JIIM).
METHODS
METHODS
Data were collected using a patient/caregiver survey via Research Electronic Data Capture (REDCap) database. Eligibility included JIIM diagnosis and current age less than 21 years old. Surveys were distributed via the CureJM organization, social media, Childhood Arthritis and Rheumatology Research Alliance (CARRA) network and Dr. Peter Dent Pediatric Rheumatology Bulletin Board.
RESULTS
RESULTS
Eighty-four respondents accessed the survey, 70 (83%) consented to participate, and 54 out of 70 completed the full survey (77%). Twenty-seven out of 57 patients (47%) tested positive for COVID-19, with 7 (12%) testing positive more than once. Despite broad usage of immunosuppressive medications, 24 out of 27 (89%) reported mild symptoms with none requiring hospitalization. Four patients reported a flare of JIIM symptoms after COVID-19; three of whom held immunomodulatory medications during their infection. Thirty-seven out of 54 respondents (69%) reported vaccination against COVID-19, with 9 out of 37 (24%) reporting minor vaccine side effects and one reporting JIIM flare post vaccination. Twenty-one out of 54 (39%) respondents reported psychosocial concerns related to the COVID-19 pandemic.
CONCLUSIONS
CONCLUSIONS
Patients with JIIM, including those on multiple immunosuppressive medications, had mild symptoms related to COVID-19. Most patients tolerated COVID-19 vaccination well. Few patients had disease flare post-COVID-19 or vaccination. Mental health concerns were demonstrated in JIIM patients during the COVID-19 pandemic.
Identifiants
pubmed: 37700267
doi: 10.1186/s12969-023-00873-0
pii: 10.1186/s12969-023-00873-0
pmc: PMC10496159
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Muscle Nerve. 2022 Oct;66(4):426-437
pubmed: 35869701
J Assoc Physicians India. 2020 Nov;68(11):20-24
pubmed: 33187031
Arch Dis Child. 2018 May;103(5):486-491
pubmed: 29434020
Semin Arthritis Rheum. 2020 Dec;50(6):1262-1268
pubmed: 33065421
Arthritis Rheumatol. 2021 Aug;73(8):e46-e59
pubmed: 34114365
J Pediatric Infect Dis Soc. 2022 Dec 7;11(Supplement_4):S132-S140
pubmed: 36063366
Arthritis Care Res (Hoboken). 2023 Jan;75(1):53-60
pubmed: 36239292
Clin Rheumatol. 2022 Oct;41(10):3189-3198
pubmed: 35701628
J Clin Immunol. 2022 Jan;42(1):25-27
pubmed: 34426906
RMD Open. 2021 Jul;7(2):
pubmed: 34312307
Rheumatol Adv Pract. 2021 Sep 13;5(3):rkab058
pubmed: 34541451
J Pediatr. 2017 May;184:38-44.e1
pubmed: 28410093
Arthritis Care Res (Hoboken). 2021 Aug;73(8):1162-1170
pubmed: 33278068
Lancet Child Adolesc Health. 2020 Jul;4(7):e17-e18
pubmed: 32411815
Enferm Clin (Engl Ed). 2019 Jul - Aug;29(4):225-233
pubmed: 29914790
Pediatr Neurol. 2021 Aug;121:26-27
pubmed: 34126319
Ann Rheum Dis. 2020 Jul;79(7):859-866
pubmed: 32471903
SN Compr Clin Med. 2023;5(1):18
pubmed: 36530960
Pediatr Rheumatol Online J. 2021 Jun 12;19(1):92
pubmed: 34118936
Pediatr Rheumatol Online J. 2021 Jun 10;19(1):86
pubmed: 34112199
Ann Rheum Dis. 2021 Jul;80(7):930-942
pubmed: 33504483
J Rheumatol. 2021 Aug;48(8):1343-1344
pubmed: 32335512